2006 - UZ Leuven

The disease occurs predominantly in men yet is increasing inincidence in women in a manner that cannot be entirely explained byincreased tobacco use.SCHOFFSKI P., DUMEZ H., CLEMENT P., HOEBEN A., PRENEN H.,WOLTER P., JONIAU S., ROSKAMS T., VAN POPPEL H.: Emerging roleof tyrosine kinase inhibitors in the treatment of advanced renal cellcancer: a review. Annals of Oncology, 2006; 17(8): 1185-1186.Advanced and metastatic renal cell cancer (RCC) is resistant toconventional chemotherapy. Only a very small number of patientssurvive long term after immunotherapy. However, any effect ofinterleukin-2 (IL-2) and/or interferon on median overall survival issmall, and treatment-associated toxicities may be severe. The diseaseis therefore an area of high unmet medical need. Activation of theVEGF and EGF/RAS/RAF/MAP kinase pathways is frequent in solidtumours such as RCC. Such activation is implicated in tumourangiogenesis and proliferation. VEGF and EGF receptors andmolecules (such as RAF kinase) involved in downstream signallingare therefore potential appropriate targets for drug therapy. Severalantibodies and low molecular weight tyrosine kinase inhibitors (TKIs)have completed phase II clinical trials. Phase II studies ofmultitargeted agents, which include inhibition of VEGFR tyrosinekinase in their repertoire (sorafenib, sunitinib and AG 013736), showclear second-line activity in metastatic RCC. The same is true of theanti-VEGF antibody, bevacizumab. In a randomised phase IIIcomparison against placebo in pretreated patients, sorafenib doubledmedian progression free survival (24 versus 12 weeks). Studies nowin progress will determine whether benefits seen second-line will alsobe evident first-line, and whether the activity of novel agents can beincreased by combining them with each other, with cytokines, or withchemotherapy.SIEMER S., VAN POPPEL H., MACHTENS S., STROHMAIER W.L.,WECHSEL H.W., GOEBELL P.J., SCHMELLER N., OBERNEDER R.,STOLZENBURG J.U., TETENS V.: Prospektiv randomisiertemultizentrische Studie zur Effektivität von TachoSil ® als Hämostypikumnach Nierenteilresektion (NT). Der Urologe Suppl.1, 2006; S107: V.8.9.Ziel: Zur Hämostase nach NT stehen heute unterschiedlicheBehandlungsmodalitäten zur Verfügung. Ziel der verliegenden Studiewar es, die Effektivität von TachoSil gegenuber der Standard-Behandlung (ST-B; Kapselnaht) zu untersuchen.150